Microbot Medical receives first international LIBERTY marketing approval
Microbot Medical received its first marketing clearance for LIBERTY outside the United States.
Evidence notes
- Israel became the second jurisdiction, after the U.S., to clear LIBERTY for marketing.
- The AMAR approval supports commercialization in Israel and a Free Sale Certificate for additional submissions.
- The approval supports Microbot Medical's path toward fielded use in maritime autonomy, underwater robotics or marine inspection workflows.
Company context
Microbot Medical develops LIBERTY, a compact single-use endovascular robotic system designed for remotely operated vascular access and navigation.